Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma is a PHASE1 clinical asset sponsored by University College, London in Primary CNS Lymphoma. SEO and diligence focus: CD19CAR T-cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.